Clinical and radiographic evaluation of melatonin and chitosan loaded nanoparticles in the treatment of periodontal intra-bony defects: A Randomized controlled clinical trial
Clinical Oral Investigations · 02.05.2025 · 29 (5)
DOI: 10.1007/s00784-025-06323-3 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, online erschienen am 02.05.2025. Verfasst von Amira Al-Agooz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Mansoura, 33516, Egypt. Hauptthemen laut MEDLINE: Melatonin, Chitosan, Alveolar Bone Loss, Nanoparticles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mansoura University.
Abstract (Originalsprache)
Objectives
The current literature lacks the effect of melatonin loaded nanoparticles (LNPs) as local drug delivery (LDD) in the treatment of periodontitis. Hence, the aim of the current study is to investigate the clinical and radiographic effects of melatonin LNPs in patients with periodontal intrabony defects.
Methods
The current study was performed on healthy patients with periodontal intrabony defects. The participants were randomly allocated into 3 groups. Group 1 received scaling and root planing (SRP) with melatonin LNPs, group 2 received placebo gel with SRP, and group 3 received SRP and chitosan LNPs. The primary outcomes included the radiographic measurements of the bone defects to evaluate the bone fill after 6 months. The secondary outcomes included the following clinical parameters; clinical attachment level (CAL), periodontal probing depth (PPD), plaque index (PI), and gingival index (GI). The clinical parameters were evaluated at baseline, 3 months, and 6 months.
Results
The current study included 67 patients with periodontal intrabony defects. All the study groups demonstrated significant improvements in all the clinical outcomes (CAL, PPD, PI, and GI) (P < 0.05). Melatonin LNPs group revealed the most significant improvement of the radiographic outcomes after 6 months including bone defect height and depth, alveolar crest level, and the buccolingual and mesiodistal width of bone defects) (P < 0.05), followed by chitosan group while insignificant changes were detected in the placebo group (P > 0.05).
Conclusion
Melatonin LNPs as a LDD can act as a promising therapeutic modality in treating periodontal intrabony defects through significant improvement of the clinical and radiographic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Mansoura, 33516, Egypt.
- Oral Medicine, Periodontology, Diagnosis and Oral Radiology Department, Faculty of Dentistry, Mansoura University, Mansoura, 33516, Egypt. shme@mans.edu.eg.
Förderung
- Mansoura University
Zitieren
APA
Al-Agooz, A., Ata, F., Saleh, W., & Elmeadawy, S. (2025). Clinical and radiographic evaluation of melatonin and chitosan loaded nanoparticles in the treatment of periodontal intra-bony defects: A Randomized controlled clinical trial. Clinical Oral Investigations, 29(5). https://doi.org/10.1007/s00784-025-06323-3
Vancouver
Al-Agooz A, Ata F, Saleh W, Elmeadawy S. Clinical and radiographic evaluation of melatonin and chitosan loaded nanoparticles in the treatment of periodontal intra-bony defects: A Randomized controlled clinical trial. Clinical Oral Investigations. 2025;29(5). doi:10.1007/s00784-025-06323-3
BibTeX
@article{AlAgooz2025,
author = {Al-Agooz, Amira and Ata, Fatma and Saleh, Wafaa and Elmeadawy, Samah},
title = {Clinical and radiographic evaluation of melatonin and chitosan loaded nanoparticles in the treatment of periodontal intra-bony defects: A Randomized controlled clinical trial},
journal = {Clinical Oral Investigations},
year = {2025},
volume = {29},
number = {5},
doi = {10.1007/s00784-025-06323-3}
}
EUVIMED